Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is adaptive therapy natural?
Frédéric Thomas, Emmanuel Donnadieu, Guillaume M. Charrière, et al.
PLoS Biology (2018) Vol. 16, Iss. 10, pp. e2007066-e2007066
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Identifying key questions in the ecology and evolution of cancer
Antoine M. Dujon, Athena Aktipis, Catherine Alix‐Panabières, et al.
Evolutionary Applications (2020) Vol. 14, Iss. 4, pp. 877-892
Open Access | Times Cited: 76
Engineering in Medicine To Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling
Morgan Craig, Adrianne L. Jenner, Bumseok Namgung, et al.
Chemical Reviews (2020) Vol. 121, Iss. 6, pp. 3352-3389
Closed Access | Times Cited: 56
Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models
Eunjung Kim, Joel S. Brown, Zeynep Eroglu, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 823-823
Open Access | Times Cited: 55
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer
Jessica J. Cunningham, Frank Thuijsman, Ralf Peeters, et al.
PLoS ONE (2020) Vol. 15, Iss. 12, pp. e0243386-e0243386
Open Access | Times Cited: 48
Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
Reza Mehdizadeh, Seyed Peyman Shariatpanahi, Bahram Goliaei, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations
Sergey Melnikov, David L. Stevens, Xian Fu, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 17924-17931
Open Access | Times Cited: 31
Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer
Helen Hockings, Eszter Lakatos, Weini Huang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Can postfertile life stages evolve as an anticancer mechanism?
Frédéric Thomas, Mathieu Giraudeau, François Renaud, et al.
PLoS Biology (2019) Vol. 17, Iss. 12, pp. e3000565-e3000565
Open Access | Times Cited: 22
Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies
Ramon Andrade de Mello, Florian Lordick, Kei Muro, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 237-247
Closed Access | Times Cited: 21
The evolution of resistance and tolerance as cancer defences
Frédéric Thomas, Mathieu Giraudeau, Flora Gouzerh, et al.
Parasitology (2019) Vol. 147, Iss. 3, pp. 255-262
Open Access | Times Cited: 18
Ecological and Evolutionary Consequences of Anticancer Adaptations
Justine Boutry, Antoine M. Dujon, Anne‐Lise Gérard, et al.
iScience (2020) Vol. 23, Iss. 11, pp. 101716-101716
Open Access | Times Cited: 18
Biophysical Approach to Understand Life and Cancer
Nuri Faruk Aykan
Aging and Cancer (2024) Vol. 5, Iss. 3, pp. 70-90
Open Access | Times Cited: 1
Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies
Derek S. Park, Kimberly A. Luddy, Mark Robertson‐Tessi, et al.
Cancer Research (2020) Vol. 80, Iss. 23, pp. 5147-5154
Open Access | Times Cited: 11
Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory
Lei Zhang, Jianli Ma, Lei Liu, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104192-104192
Open Access | Times Cited: 3
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
Orlando Musso, Naiara Beraza
Gut (2019) Vol. 68, Iss. 10, pp. 1728-1730
Open Access | Times Cited: 8
Modeling genetic heterogeneity of drug response and resistance in cancer
Teemu D. Laajala, Travis Gerke, Svitlana Tyekucheva, et al.
Current Opinion in Systems Biology (2019) Vol. 17, pp. 8-14
Open Access | Times Cited: 6
The value of treating cancer as an evolutionary disease
James Shapiro, Denis Noble
Progress in Biophysics and Molecular Biology (2021) Vol. 165, pp. 1-2
Closed Access | Times Cited: 6
Understanding the potential benefits of adaptive therapy for metastatic melanoma
Eunjung Kim, Joel S. Brown, Zeynep Eroglu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 4
Adaptive Therapy: Using Evolutionary Game Theory to Combat Cancer Treatment Resistance
L Iyer, Becca Brooks
Journal of Student Research (2024) Vol. 13, Iss. 1
Open Access
Beyond Peto’s Paradox: Expanding the Study of Cancer Resistance Across Species
Antoine M. Dujon, Amy M. Boddy, Rodrigo Hamede, et al.
Evolution (2024) Vol. 79, Iss. 1, pp. 6-10
Open Access
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer
Uma Mukherjee, Helen Hockings, Nicholas Counsell, et al.
BMJ Open (2024) Vol. 14, Iss. 12, pp. e091262-e091262
Open Access
Interdisciplinary approaches to metastasis
S W Smye, Robert A. Gatenby
iScience (2022) Vol. 25, Iss. 9, pp. 105015-105015
Open Access | Times Cited: 2
Ecoevolutionary biology of pancreatic ductal adenocarcinoma
Glancis L. Raja Arul, Merih D. Toruner, Robert A. Gatenby, et al.
Pancreatology (2022) Vol. 22, Iss. 6, pp. 730-740
Closed Access | Times Cited: 2
Nous sommes tous au minimum des cancéreux asymptomatiques
Frédéric Thomas, Marie-Neige Cordonnier
Pour la Science (2019) Vol. N° 505 - novembre, Iss. 11, pp. 34-39
Closed Access | Times Cited: 1
Delaying Emergence of Resistance to KRAS Inhibitors with Adaptive Therapy: “Treatment-to-Contain” Instead of “Treatment-to-Cure”
Amir Imran Faisal Hamdi, Johnson Stanslas
ONCOLOGIE (2022) Vol. 24, Iss. 2, pp. 185-194
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top